Systemic Inflammatory and Hematological Profiles in Triple-Negative Breast Cancer: A Study from a Senegalese Cohort

Background/Objectives: Triple-negative breast cancer (TNBC) is an aggressive subtype associated with a poor prognosis and limited treatment options. Inflammatory and hematological biomarkers have emerged as potential tools for disease characterization, particularly in low-resource settings. Methods: This cross-sectional analytical study was conducted between July 2022 and February 2024 at Dalal Jamm Hospital in Dakar, Senegal, and included 120 women: 40 with TNBC, 40 with hormone-dependent breast cancer (HDBC), and 40 healthy controls. Blood samples were collected at diagnosis before any treatment to measure complete blood counts and C-reactive protein (CRP) levels. Inflammatory ratios—neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR)—were calculated. Results: TNBC patients displayed a distinct inflammatory profile characterized by elevated neutrophil counts, CRP, NLR, and MLR, as well as reduced lymphocyte and basophil percentages compared to healthy controls. NLR > 1.12 demonstrated strong discriminatory ability (AUC = 0.847; sensitivity 90%; specificity 65%). Differences between TNBC and HDBC were less pronounced, except for CRP and basophil levels. Multivariate analysis confirmed independent associations of elevated NLR, CRP, and neutrophils with TNBC. Conclusions: These findings provide new insights into the inflammatory and hematological characteristics of TNBC in this population and support further investigation of accessible biomarkers for early disease stratification in similar settings.